HUD schedules $93 million healthcare mortgage-loan sale for August 11
The U.S. Department of Housing and Urban Development has scheduled a sealed-bid sale of 14 federally held commercial mortgage loans backed by 13 healthcare properties, putting a portfolio with an unpaid principal balance of approximately $93 million on track for disposition.
HUD’s Office of Asset Sales identified the transaction as Healthcare Loan Sale 2026-2 and set the sale for August 11, 2026. The agency’s notice was dated July 29, 2026.
The scheduled transaction concerns due-and-payable, Secretary-held loans under the Federal Housing Administration’s Section 232 healthcare program. The loans are commercial mortgage assets connected to healthcare properties, rather than ordinary single-family home mortgages.
What HUD is offering
The portfolio includes 14 Section 232 healthcare mortgage loans backed by 13 properties. The number of loans is therefore larger than the number of properties, although the approved material does not provide a property-by-property breakdown.
HUD puts the combined unpaid principal balance at approximately $93 million. That figure describes the principal still unpaid on the loans; it is not the price HUD will necessarily receive in the sale.
The available notice does not identify the individual healthcare properties, their locations or the balances of individual loans. It also does not provide a sale price or the names of winning bidders before the scheduled transaction.
HUD has reserved the right to add or remove loans from Healthcare Loan Sale 2026-2. As a result, the portfolio offered on August 11 could differ from the announced group of 14 loans backed by 13 properties.
Why the transaction matters
The sale creates a defined near-term event in the federal management of mortgage assets. It gives the commercial housing-finance market a specific date, portfolio size and approximate outstanding principal balance to track.
It also involves financing tied to healthcare properties, making the transaction relevant beyond the raw value of the loans. Changes in ownership or servicing of commercial mortgage assets can matter to the parties involved in those loans, including healthcare-property borrowers and other participants in the financing process.
Still, the approved information does not establish how the scheduled sale would affect any individual property, borrower or healthcare operation. It also does not support a claim that the transaction will materially change national mortgage rates, home prices or overall housing affordability.
The sale should not be described as a foreclosure based on the available material. HUD characterizes the assets as due-and-payable, Secretary-held Section 232 loans, but the notice does not establish foreclosure status.
What happens next
HUD is scheduled to conduct the sealed-bid sale on August 11, 2026. Until that process occurs, the eventual sale prices and winning bidders remain unknown in the approved source material.
The agency may revise the group of loans before the sale by adding or removing assets. That reservation means the final offering may not match every detail in the initial announcement.
For now, the confirmed elements are the transaction name, sale date, loan type, portfolio count and approximate unpaid principal balance: Healthcare Loan Sale 2026-2, August 11, 2026, 14 Section 232 healthcare mortgage loans, 13 backed properties and approximately $93 million in unpaid principal.
HUD’s Office of Asset Sales is the agency office identified with the transaction. Further details about the final portfolio, sale outcome and winning bidders were not included in the approved material.
Sources
- Office of Asset Sales: Healthcare Loan Sale 2026-2, U.S. Department of Housing and Urban Development
- HUD News, U.S. Department of Housing and Urban Development
Look for updates to this story
Discover more from Interactive News
Subscribe to get the latest posts sent to your email.